<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03788772</url>
  </required_header>
  <id_info>
    <org_study_id>APHP180016</org_study_id>
    <secondary_id>2018-A01934-51</secondary_id>
    <nct_id>NCT03788772</nct_id>
  </id_info>
  <brief_title>Systems Analysis of Antigen Presenting Cells in Human Sepsis</brief_title>
  <acronym>DENDRISEPSIS</acronym>
  <official_title>Systems Analysis of Antigen Presenting Cells in Human Sepsis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is a common life-threatening inflammatory response to infection and is the leading&#xD;
      cause of death in the intensive care unit. Septic patients exhibit a complex&#xD;
      immunosuppressive response affecting both innate and adaptive components of immunity, with a&#xD;
      possible link to nosocomial infections. However, the molecular and cellular mechanisms&#xD;
      resulting in secondary immunosuppression remain poorly understood, but may involve the&#xD;
      antigen-presenting cells (APC, including dendritic cells and monocytes/macrophages) that link&#xD;
      innate and adaptive immunity. Furthermore, the increasing phenotypic and functional&#xD;
      heterogeneity of APC subsets raise the question of their respective role in sepsis. We&#xD;
      propose to address the pathophysiologal role of APC using systems biology approaches in human&#xD;
      sepsis.&#xD;
&#xD;
      The objective is to go from low- to high-resolution analysis of APC subset diversity and&#xD;
      underlying molecular and functional features in sepsis. The global objective will be reached&#xD;
      through:&#xD;
&#xD;
        1. Systematic description and phenotypic analysis of circulating APC subsets in sepsis&#xD;
&#xD;
        2. Association of APC subsets distribution, phenotype and function with severe sepsis&#xD;
           physiopathology and relevant clinical outcomes (ICU-acquired infections and death)&#xD;
&#xD;
        3. High-resolution molecular profiling of circulating APC subsets using population level&#xD;
           and single cell RNAseq.&#xD;
&#xD;
      To this aim, the investigator designed a prospective interventional study in order to collect&#xD;
      blood samples at significant time points in patients with sepsis or septic shock (the&#xD;
      population of interest) and relevant control subjects, either critically ill patients with&#xD;
      non-septic acute circulatory failure or age-matched healthy subjects. The study's&#xD;
      intervention is limited to additional blood samples. The risks and constraints are related to&#xD;
      additional blood samples (maximum 120mL), which will be performed either from an arterial&#xD;
      catheter when present in ICU patients, or from a venous puncture for patients without&#xD;
      arterial catheters and for healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2019</start_date>
  <completion_date type="Anticipated">July 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ICU-acquired infections (nosocomial infections)</measure>
    <time_frame>up to 3 months after the inclusion</time_frame>
    <description>Infections not present at the time of ICU admission and diagnosed at least after 48 hours in the ICU</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-hospital death</measure>
    <time_frame>up to 3 months after the inclusion</time_frame>
    <description>date of death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Sepsis</condition>
  <condition>Acute Circulatory Failure</condition>
  <arm_group>
    <arm_group_label>Adults patients hospitalized in ICU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients hospitalized in the intensive care unit (ICU) for severe infections (sepsis and septic shock) or or non-septic shock (cardiogenic or hemorrhagic shock)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multiple blood sampling</intervention_name>
    <description>ICU septic and non-septic patients will be subjected to repeated blood samples at the following time-points: ICU admission, day 4/5, ICU and hospital discharge, 3 months. Patients exhibiting ICU-acquired infection will also be sampled at the time of diagnosis (up to 6 additional blood samples of 20 mL within 3 months = 120mL)</description>
    <arm_group_label>Adults patients hospitalized in ICU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Simple blood sampling</intervention_name>
    <description>Healthy controls (blood donors and patients undergoing elective cataract surgery) will be subjected to one single blood sample of 20 mL.</description>
    <arm_group_label>Adults patients hospitalized in ICU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ICU patients with severe infections (Sepsis-3 definitions):&#xD;
&#xD;
             clinically or microbiologically documented infection and organ dysfunction graded as&#xD;
             follows:&#xD;
&#xD;
               -  Sepsis: increase in the Sequential Organ Failure Assessment (SOFA) score of 2&#xD;
                  points or more.&#xD;
&#xD;
               -  Septic shock: vasopressor requirement to maintain a mean arterial pressure ≥&#xD;
                  65mmHg and serum lactate level &gt; 2 mmol/L in the absence of hypovolemia&#xD;
&#xD;
          2. ICU patients with non-septic acute circulatory failure:&#xD;
&#xD;
               -  Cardiogenic shock: left ventricle systolic dysfunction (echocardiographic left&#xD;
                  ventricular ejection fraction &lt; 45%) and the need of vasopressor (norepinephrine&#xD;
                  at any dose and inotropic support (dobutamine ≥ 5 µg/kg/min or epinephrine at any&#xD;
                  dose) in the absence of patent infection.&#xD;
&#xD;
               -  Severe hemorrhage: hypotension with acute blood loss requiring transfusion of at&#xD;
                  least four packed red cells within 24h and vasopressor support by norepinephrine&#xD;
                  or epinephrine at any dose.&#xD;
&#xD;
          3. Healthy controls:&#xD;
&#xD;
               -  Blood donors&#xD;
&#xD;
               -  Patients undergoing elective cataract surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. All ICU patients&#xD;
&#xD;
               -  hematological malignancy (or significant history of bone marrow disease),&#xD;
&#xD;
               -  HIV infection at any stage,&#xD;
&#xD;
               -  any immunosuppressive drugs including corticosteroids ≥ 0.5 mg/kg equivalent&#xD;
                  prednisone per day for more 7 days,&#xD;
&#xD;
               -  anticancer chemotherapy or chemotherapy received during the last three months&#xD;
                  before inclusion&#xD;
&#xD;
               -  bone marrow or solid organ transplantation,&#xD;
&#xD;
               -  leucopenia (&lt;1000/mm3) excepted if due to sepsis,&#xD;
&#xD;
               -  pregnancy&#xD;
&#xD;
               -  do-not-resuscitate order at ICU admission&#xD;
&#xD;
               -  patients under legal protection regimen.&#xD;
&#xD;
          2. Healthy controls&#xD;
&#xD;
               -  history of inflammatory disease&#xD;
&#xD;
               -  hematological malignancy (or significant history of bone marrow disease),&#xD;
&#xD;
               -  HIV infection at any stage,&#xD;
&#xD;
               -  any immunosuppressive drugs including corticosteroids ≥ 0.5 mg/kg equivalent&#xD;
                  prednisone per day for more 7 days,&#xD;
&#xD;
               -  anticancer chemotherapy or immunotherapy received during the last three months&#xD;
                  before inclusion&#xD;
&#xD;
               -  bone marrow or solid organ transplantation,&#xD;
&#xD;
               -  pregnancy&#xD;
&#xD;
               -  infectious symptoms within the previous month&#xD;
&#xD;
               -  subjects under legal protection regimen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric PENE, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vassili SOUMELIS, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frédéric PENE, MD PhD</last_name>
    <phone>+33 1 58 41 46 77</phone>
    <email>frederic.pene@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cochin Hospital, AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric PENE, MD PhD</last_name>
      <phone>+33 1 58 41 46 77</phone>
      <email>frederic.pene@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>December 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2018</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dendritic cell</keyword>
  <keyword>sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

